Hofseth Biocare

Hofseth Biocare's reported carbon emissions

Hofseth Biocare, a pharmaceutical preparation manufacturer headquartered in Norway, reported its carbon emissions for several years. In 2024, the company’s total reported emissions were approximately 14,930,000 kg CO2e. This figure includes Scope 1 emissions of about 1,616,000 kg CO2e, Scope 2 emissions of approximately 15,000 kg CO2e, and Scope 3 emissions totalling around 13,271,000 kg CO2e. Scope 3 emissions in 2024 were broken down into purchased goods and services, which accounted for about 11,368,000 kg CO2e, upstream transportation and distribution at approximately 445,000 kg CO2e, and downstream transportation and distribution at roughly 1,453,000 kg CO2e. Prior to 2024, Hofseth Biocare primarily disclosed Scope 1 and Scope 2 emissions. In 2023, Scope 1 emissions were approximately 1,850,000 kg CO2e, with Scope 2 emissions at about 15,000 kg CO2e. For 2022, Scope 1 emissions were reported as 2,104,000 kg CO2e and Scope 2 emissions were around 15,000 kg CO2e. In 2021, Scope 1 emissions were approximately 1,810,000 kg CO2e and Scope 2 emissions stood at about 45,000 kg CO2e. The earliest reported year, 2020, shows Scope 1 emissions of approximately 1,619,000 kg CO2e and Scope 2 emissions of about 90,400 kg CO2e. Hofseth Biocare’s disclosures indicate that Scope 3 emissions data, specifically for purchased goods and services, was not available for the 2020-2023 reporting periods. The company has not publicly announced specific carbon reduction targets or climate commitments, nor has it outlined any Science Based Targets initiative (SBTi) reduction targets. As the company is not cascading emissions data from a parent organization, all reported figures are attributed directly to Hofseth Biocare ASA.